{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:15:23Z","timestamp":1784945723647,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.msard.2024.106221","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T22:37:08Z","timestamp":1733697428000},"page":"106221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["COVID-19 in patients with multiple sclerosis\u2014A narrative review"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-698X","authenticated-orcid":false,"given":"Bijay Kumar","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eru","family":"Sujakhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smruti","family":"Karale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Madhavi Latha","family":"Telagarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2024.106221_bib0001","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106221_bib0002","article-title":"The effect of COVID-19 on multiple sclerosis relapse: a systematic review and meta-analysis","volume":"81","author":"Aghajanian","year":"2024","journal-title":"Mult. Scler. Rel. Disord."},{"key":"10.1016\/j.msard.2024.106221_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104156","article-title":"COVID-19 severity among patients with multiple sclerosis treated with cladribine: a systematic review and meta-analysis","volume":"68","author":"Albanese","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2024.106221_bib0004","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12035-020-02134-7","article-title":"Neurological complications associated with the blood-brain barrier damage induced by the inflammatory response during SARS-CoV-2 infection","volume":"58","author":"Alquisiras-Burgos","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.msard.2024.106221_bib0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jocn.2022.02.033","article-title":"Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: an observational study in the Middle East","volume":"99","author":"Alroughani","year":"2022","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2024.106221_bib0006","series-title":"Empowering People Affected By MS to Live Their Best Lives","year":"2024"},{"key":"10.1016\/j.msard.2024.106221_bib0007","unstructured":"Anon, The different types of COVID-19 vaccines. Accessed October 1, 2024. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-race-for-a-covid-19-vaccine-explained."},{"issue":"11","key":"10.1016\/j.msard.2024.106221_bib0008","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/jcmm.17747","article-title":"Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: a systematic review","volume":"27","author":"Arabi","year":"2023","journal-title":"J. Cell Mol. Med."},{"issue":"7","key":"10.1016\/j.msard.2024.106221_bib0009","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","article-title":"Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host\u2013virus interaction, and proposed neurotropic mechanisms","volume":"11","author":"Baig","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.msard.2024.106221_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102174","article-title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","volume":"43","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2024.106221_bib0011","doi-asserted-by":"crossref","first-page":"9231","DOI":"10.3390\/ijms24119231","article-title":"COVID-19: the course, vaccination and immune response in people with multiple sclerosis: systematic review","volume":"24","author":"Bazylewicz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2024.106221_bib0012","doi-asserted-by":"crossref","first-page":"e761","DOI":"10.1212\/NXI.0000000000000761","article-title":"COVID-19 and MS disease-modifying therapies","volume":"7","author":"Berger","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2024.106221_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200163","article-title":"mRNA COVID-19 vaccination does not exacerbate symptoms or trigger neural antibody responses in multiple sclerosis","volume":"10","author":"Blanco","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2024.106221_bib0014","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/brainsci10060345","article-title":"COVID-19 immunopathology and the central nervous system: implication for multiple sclerosis and other autoimmune diseases with associated demyelination","volume":"10","author":"Boziki","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2024.106221_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102734","article-title":"COVID-19 in teriflunomide-treated patients with multiple sclerosis: a case report and literature review","volume":"48","author":"Capone","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2024.106221_bib0016","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1007\/s00415-021-10545-2","article-title":"Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus","volume":"268","author":"Centonze","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.106221_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.680188","article-title":"Differential cytokine responses in hospitalized COVID-19 patients limit efficacy of remdesivir","volume":"12","author":"Chan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2024.106221_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117147","article-title":"COVID-19 in multiple sclerosis patients and risk factors for severe infection","volume":"418","author":"Chaudhry","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2024.106221_bib0019","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1177\/13524585211061343","article-title":"Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within multiple sclerosis partners advancing technology and health solutions","volume":"28","author":"Cohen","year":"2022","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.106221_bib0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200043","article-title":"Longitudinal postvaccine SARS-CoV-2 immunoglobulin G titers, memory b-cell responses, and risk of COVID-19 in multiple sclerosis over 1 Year","volume":"10","author":"Disanto","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"17","key":"10.1016\/j.msard.2024.106221_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00404-18","article-title":"Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43","volume":"92","author":"Dub\u00e9","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2024.106221_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120518","article-title":"Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine","volume":"444","author":"Etemadifar","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2024.106221_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neurol.2021.10.003","article-title":"Risk factors of severe COVID-19 in people with multiple sclerosis : a systematic review and meta-analysis","volume":"178","author":"Etemadifar","year":"2022","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2024.106221_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102915","article-title":"COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect?","volume":"51","author":"Etemadifar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2024.106221_bib0025","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1177\/1352458520978354","article-title":"Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis","volume":"27","author":"Ferreira","year":"2021","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.106221_bib0026","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J."},{"issue":"2","key":"10.1016\/j.msard.2024.106221_bib0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/1568026622666220707114121","article-title":"Therapeutics for the management of cytokine release syndrome in COVID-19","volume":"23","author":"Ghosh","year":"2023","journal-title":"Curr. Top. Med. Chem."},{"issue":"3","key":"10.1016\/j.msard.2024.106221_bib0028","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s10072-021-05846-3","article-title":"Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis","volume":"43","author":"Hada","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2024.106221_bib0029","article-title":"COVID-19 in ocrelizumab-treated people with multiple sclerosis","volume":"49","author":"Hughes","year":"2021","journal-title":"Mult. Scler. Rel. Disord."},{"key":"10.1016\/j.msard.2024.106221_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2020.100287","article-title":"A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies","volume":"21","author":"Kataria","year":"2020","journal-title":"eNeurologicalSci"},{"issue":"8","key":"10.1016\/j.msard.2024.106221_bib0031","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1177\/13524585231185246","article-title":"Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: an observational study by the New York COVID-19 neuro-immunology consortium (NYCNIC-2)","volume":"29","author":"Klineova","year":"2023","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2024.106221_bib0032","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/acn3.51342","article-title":"Multiple sclerosis, rituximab, and COVID-19","volume":"8","author":"Langer-Gould","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.106221_bib0033","first-page":"318","article-title":"Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19","volume":"81","author":"Liu","year":"2020","journal-title":"J. Infec."},{"issue":"3","key":"10.1016\/j.msard.2024.106221_bib0034","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/13524585221103787","article-title":"Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: an observational study","volume":"29","author":"Magn\u00e8","year":"2023","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2024.106221_bib0035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/jcp.29937","article-title":"COVID-19 and olfactory dysfunction: a possible associative approach towards neurodegenerative diseases","volume":"236","author":"Mahalaxmi","year":"2021","journal-title":"J. Cell Physiol."},{"issue":"2","key":"10.1016\/j.msard.2024.106221_bib0036","article-title":"Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis","volume":"8","author":"Marrie","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"8","key":"10.1016\/j.msard.2024.106221_bib0037","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/1352458518775550","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"Mills","year":"2018","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2024.106221_bib0038","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/jcm9124067","article-title":"Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases","volume":"9","author":"M\u00f6hn","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2024.106221_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105921","article-title":"Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review","volume":"194","author":"Montalvan","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.msard.2024.106221_bib0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijid.2020.03.062","article-title":"A first case of meningitis\/encephalitis associated with SARS-Coronavirus-2","volume":"94","author":"Moriguchi","year":"2020","journal-title":"Int. J. Infec. Dis."},{"issue":"15","key":"10.1016\/j.msard.2024.106221_bib0041","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1128\/JVI.00737-08","article-title":"Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2","volume":"82","author":"Netland","year":"2008","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.msard.2024.106221_bib0042","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neur. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2024.106221_bib0043","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10072-022-06447-4","article-title":"Characteristics and management of multiple sclerosis patients during the Omicron era: is there a concern about the MS course in the face of the new variant of COVID-19?","volume":"44","author":"Paybast","year":"2023","journal-title":"Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2024.106221_bib0044","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000529982","article-title":"Summary of safety and efficacy of COVID vaccination in patients with multiple sclerosis","volume":"86","author":"Pernicov\u00e1","year":"2023","journal-title":"Eur. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.106221_bib0045","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10072-022-06559-x","article-title":"COVID-19 vaccine hesitancy among Italian people with multiple sclerosis","volume":"44","author":"Proietti","year":"2023","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2024.106221_bib0046","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00415-021-10803-3","article-title":"Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies","volume":"269","author":"Prosperini","year":"2022","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.106221_bib0047","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","article-title":"COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies","volume":"35","author":"Reder","year":"2021","journal-title":"CNS. Drugs"},{"issue":"6","key":"10.1016\/j.msard.2024.106221_bib0048","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.106221_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104494","article-title":"CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis","volume":"70","author":"Schiavetti","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106221_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103358","article-title":"Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis","volume":"57","author":"Schiavetti","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106221_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102800","article-title":"COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: a systematic review","volume":"50","author":"Sharifian-Dorche","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.106221_bib0052","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.106221_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104042","article-title":"Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy","volume":"80","author":"Sormani","year":"2022","journal-title":"EBioMedicine"},{"issue":"4-5","key":"10.1016\/j.msard.2024.106221_bib0054","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/13524585221150881","article-title":"Safety of COVID-19 vaccines in multiple sclerosis: a systematic review and meta-analysis","volume":"29","author":"Stefanou","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.106221_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198197","article-title":"The role of dysregulated immune responses in COVID-19 pathogenesis","volume":"290","author":"Tahaghoghi-Hajghorbani","year":"2020","journal-title":"Virus Res."},{"issue":"4","key":"10.1016\/j.msard.2024.106221_bib0056","doi-asserted-by":"crossref","first-page":"151","DOI":"10.7224\/1537-2073.2020-037","article-title":"Disease-modifying therapies during the COVID-19 outbreak: a narrative review of international and national recommendations","volume":"22","author":"Thakolwiboon","year":"2020","journal-title":"Int. J. MS Care"},{"issue":"26","key":"10.1016\/j.msard.2024.106221_bib0057","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1056\/NEJMc2009191","article-title":"Guillain\u2013Barr\u00e9 syndrome associated with SARS-CoV-2","volume":"382","author":"Toscano","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.106221_bib0058","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/vaccines10010037","article-title":"COVID-19 vaccines cost-effectiveness analysis: a scenario for Iran","volume":"10","author":"Vaezi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.msard.2024.106221_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102182","article-title":"A fine balance: immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19","volume":"42","author":"Valencia-Sanchez","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.106221_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104102","article-title":"Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2024.106221_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103225","article-title":"MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis","volume":"56","author":"Yamout","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2024.106221_bib0062","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1007\/s10072-022-06051-6","article-title":"COVID-19 vaccines and patients with multiple sclerosis: willingness, unwillingness and hesitancy: a systematic review and meta-analysis","volume":"43","author":"Yazdani","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2024.106221_bib0063","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-3-030-85109-5_13","article-title":"Cytokine storm and failed resolution in COVID-19: taking a cue from multiple sclerosis","volume":"1352","author":"Zahoor","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.msard.2024.106221_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110195","article-title":"New understanding of the damage of SARS-CoV-2 infection outside the respiratory system","volume":"127","author":"Zhang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.msard.2024.106221_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101642","article-title":"Sars-Cov-2: underestimated damage to nervous system","volume":"36","author":"Zhou","year":"2020","journal-title":"Travel Med. Infec. Dis."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T20:59:50Z","timestamp":1738184390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824007971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":65,"alternative-id":["S2211034824007971"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106221","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 in patients with multiple sclerosis\u2014A narrative review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106221"}}